Highlights PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
3.56 ^USD	+5.33%		+0.71%	-28.37%

May. 15	PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 10	NetScientific says PDS Biotech's Versamune meets endpoints	AN

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
NetScientific says PDS Biotech's Versamune meets endpoints	May. 10	AN
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study	May. 10	MT
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer	May. 09	CI
Empire Metals targets key milestones in Australia	Mar. 27	AN
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
PDS Biotechnology Corporation Announces Publication of Preclinical Research	Mar. 13	CI
Pds Biotech Announces CFO Changes	Nov. 28	CI
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients	Nov. 09	CI
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO	23-10-23	CI
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	23-10-11	CI
PDS Biotechnology Corporation Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA	23-10-03	CI
PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies	23-09-20	CI
NetScientific's PDS suffers wider loss as R&D costs mount	23-08-14	AN
PDS Biotechnology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial	23-08-14	CI
PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023	23-07-25	CI
Pds Biotech Announces Acceptance of Abstract on Combination of Pds0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute At Cytokines 2023	23-07-17	CI
PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of VersamuneÂ®? and PDS0301	23-07-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Highlights

Filters